The pursuit of ignorance
The UK’s anti-lobbying clause will jeopardise evidence informed policy making

K E Smith reader1, J Collin professor1, B Hawkins lecturer2, S Hilton deputy director3, L Moore, director3

1Global Public Health Unit, School of Social and Political Science, University of Edinburgh, Edinburgh, UK; 2Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK; 3MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK

“‘There is nothing a government hates more than to be well informed; for it makes the process of arriving at decisions much more complicated and difficult.’”

John Maynard Keynes

Despite Keynes’s belief that evidence makes government decisions harder, successive UK governments have committed to adopting policies informed by evidence. UK academics now have explicit incentives to demonstrate the impact of their research beyond academia. Surprisingly, however, the UK Cabinet Office has introduced a clause that could limit researchers’ engagement in policy debates.

The new clause, for insertion into all grant agreements, was announced by Cabinet Office minister, Matthew Hancock. It prohibits the use of government funds for “activity intended to influence or attempt to influence Parliament, government or political parties, or attempting to influence the awarding or renewal of contracts and grants, or attempting to influence legislative or regulatory action.” This seems to conflict with the pursuit of public health goals, which often require ensuring policy makers are aware of the implications of research.

The tension may be inadvertent on the part of the government, but at the very least it seems to have uncritically adopted the agenda of the Institute of Economic Affairs (IEA), the free market think tank cited in the announcement of the clause. Two IEA reports appear to underlie the clause, both presenting sustained critiques of public health advocates and researchers. The IEA’s position is that only money raised through sources other than taxation should be used to influence government spending, in effect privileging private sector views, some of which clearly run counter to public health. It is worth noting that the IEA has received substantial funding from leading tobacco manufacturers, while Hancock was recently reported to have received donations from the IEA chair (without breaching parliamentary rules governing donations to MPs).

The seriousness of the threat posed by this new clause for policy engaged health researchers depends on its interpretation, but it seems likely to reinforce what a systematic review identified as the two key barriers to the use of research in policy: poor dissemination or accessibility of research and lack of clarity about relevance to policies.

It is on the back of such evidence that UK Research Councils (RCUK) and the higher education funding councils have encouraged academics to become more outward facing. A core example is the ESRC’s “impact accelerator” awards. At the University of Edinburgh, such funding has supported researchers mapping Scotland’s tobacco and alcohol retail outlets to make their results publicly available and to discuss the policy implications of the clear evidence of oversupply in deprived communities. The wording of the new clause suggests that research councils will no longer be able to support these impact oriented grants.

The clause also seems to threaten the multifunded UKCRC public health research centres of excellence, established to encourage researchers to engage with policy makers and practitioners, and the government funded What Works centres, intended “to improve the way government and other organisations create, share, and use … high quality evidence for decision-making,” a concept Hancock has previously praised.

Leaving aside those who undertake research projects directly commissioned by RCUK or government departments, the wider threat seems greatest for those funded by, or working in, research centres and units that are core funded by the RCUK. The picture is more complex for traditional university academics, but even then time not covered by direct grant income or teaching includes support from the government, through grants from the higher education councils. To take one example of work that could be prevented, researchers who found that NHS organisations with private finance initiative contracts had higher capital costs than those without such contracts, “worked closely with several parliamentary committees, including the House of Commons Public Accounts and Treasury Committees, the House of Lords Economic Affairs Committee, and the Scottish

Correspondence to: K E Smith Katherine.smith@ed.ac.uk
Parliament’s Finance Committee, to ensure that the research has informed legislative opinion and impacted on its decision-making. The purpose was to reduce costs to the public purse, and yet the new clause seems to rule out this kind of activity unless academics are funded by sources other than the government.

The epidemiologist Austin Bradford Hill, famous for his work with Richard Doll showing the link between smoking and lung cancer, said he had initially believed that, as a researcher he had “no part to play in telling the public about those results,” lest such efforts come across as “propaganda.” Bradford Hill and Doll later radically revised this view; in public health, we rightly demand more of our researchers and (until now) so have UK governments. The need to improve the use of scientific evidence in policy making is clear; this clause limits the ability of government funded researchers to help achieve this, privileging those working to influence policy on behalf of commercial interests.

Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following: KS is a board member of ASH Scotland and receives grants from the Economic and Social Research Council. JC receives grants from the Economic and Social Research Council. He advises the Institute of Alcohol Studies and is a committee member of the Tobacco Advisory Group of Cancer Research UK. He is a coinvestigator of the UK Centre for Tobacco and Alcohol Studies. BH’s time is funded in part by the National Cancer Institute, US National Institutes of Health. LM and SH are funded by the Medical Research Council and the Chief Scientist Office of the Health and Social Care Directorates. LM is a member of the methodology research programme funding board of MRC’s Public Health Strategy Group.

Provenance and peer review: Commissioned; not externally peer reviewed.


Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions

For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe